Abstract
Several biomarkers from MS patients’ biological fluid have been evaluated to support a more precise diagnosis, to predict disease course, and to evaluate treatment response. We investigated the diagnostic and prognostic value of CSF concentration of target biomarkers in both relapsing (RMS = 107) and progressive (PMS = 18) MS patients and in other inflammatory (OIND = 10) and non-inflammatory (ONIND = 15) neurological disorders.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
